Publication date: Jun 24, 2025
Guy Goodwin, MD Credit: Compass PathwaysCompass Pathways announced positive phase 3 data from its ongoing COMP005 trial, which evaluates its synthetic psilocybin formulation COMP360 for treatment-resistant depression (TRD). The trial showed a consistent safety profile compared to earlier trials on COMP360 with no new safety findings. The company expects to announce 26-week data from COMP006 in the second half of 2026. June 23, 2025. https://www. businesswire. com/news/home/20250623615674/en/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression.
| Concepts | Keywords |
|---|---|
| Businesswire | Blinded |
| June | Comp005 |
| Medicated | Comp006 |
| Week | Comp360 |
| Compass | |
| Depression | |
| Evaluating | |
| Pathways | |
| Phase | |
| Positive | |
| Psilocybin | |
| Trd | |
| Treatment | |
| Trial | |
| Week |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Methionine |
| disease | MESH | depression |
| drug | DRUGBANK | Psilocybine |
Original Article
(Visited 3 times, 1 visits today)